Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Drug Rebate Contracts with Option to Join - 0004-Rvbeitr.59-2023

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Various Open House Contracts 2023

Medicines Contracts with Accession Option

Pharmaceutical Representative with Accession Data

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Ciclospiron, Atc S01xa18 for the Period April 1St, 2023 - March 31St, 2025

Open House Drug Discount Agreements Rotigotine, Atc N04bc09

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Dasatinib, Atc L01ea02 for the Period 04/01/2023 - 03/31/2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Evolocumab, Atc C10ax13 for the Period April 1St, 2023 - March 31St, 2025